All conditions

Uveitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

451
Trials on record
46
Recruiting now
3
Australian sites
5
Phase 3 trials
4
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Uveitis →

Get alerts when Uveitis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Uveitis

Uveitis is a condition where the middle layer of the eye, called the uvea, becomes inflamed. The uvea sits between the outer white part of the eye and the inner retina, and it contains many of the blood vessels that supply the eye. When this tissue becomes inflamed, it can cause symptoms such as redness, pain, blurred vision, sensitivity to light, and sometimes floaters — those small shapes that drift across your field of vision. The condition can affect one or both eyes, and it can develop quickly or build up gradually over time. In some cases, uveitis is linked to other conditions in the body, such as autoimmune or inflammatory diseases, while in other cases no clear underlying cause is found.

Uveitis is not rare in Australia. It is estimated to affect tens of thousands of Australians and is one of the more significant causes of vision loss in working-age adults in the country. It can occur at any age, including in children, and affects both men and women. Because it can look similar to other eye conditions at first, it is important that it is diagnosed and managed by an eye specialist, often an ophthalmologist, and sometimes in partnership with other specialists depending on whether an underlying cause has been identified.

Treatment generally focuses on reducing the inflammation in the eye and protecting vision. Depending on the type and severity of the condition, doctors may use eye drops, injections around or into the eye, or medications taken by mouth or given through an infusion. Some people experience a single episode that settles with treatment, while others find the condition comes and goes over time and requires longer-term management. Regular monitoring by an eye specialist is an important part of care, as uveitis can sometimes lead to complications such as cataracts, glaucoma, or damage to the retina if it is not well controlled.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Uveitis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Uveitis

4 medicines listed on the PBS for Uveitis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 4 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
betamethasone acetate + betamethasone sodium phosphate Celestone Chronodose Uveitis AU$15.03 Restricted benefit
prednisolone acetate + phenylephrine Prednefrin Forte Uveitis AU$9.91 Restricted benefit
Dexamethasone Ozurdex Non-infectious posterior segment uveitis AU$1091.84 Authority required
Adalimumab Humira, Hadlima, Hyrimoz +2 more non-infectious uveitis Vision threatening AU$272.84 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Uveitis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Uveitis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Uveitis by country. Australia is highlighted.

Showing the top 10 of 51 countries with trial sites.

Clinical trials for Uveitis

Showing 133 of 133 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00132691 · JHSPH Center for Clinical Trials Phase 4 · 3 countries Completed
Completed Phase 4 Est. completion 1 December 2010
🇦🇺 AU🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are 13 years old or older - You have at least some vision (able to detect hand movement or better) in at least one eye affected by uveitis - The pressure inside your affected eye(s) is at a normal or acceptable level (24 mm Hg or lower) Who may not be able to join: - You hav...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT00333814 · Allergan Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 1 December 2008
🇦🇺 AU🇦🇹 AT🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇬🇷 GR +10 more

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with a long-term inflammatory eye condition called chronic intermediate uveitis in at least one eye Who may not be able to join: - You have a serious illness or health condition that is not currently under control - You curre...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01829295 · University of California, San Francisco Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 21 February 2018
🇦🇺 AU🇮🇳 IN🇲🇽 MX🇸🇦 SA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a non-infectious form of uveitis (inflammation inside the eye) affecting one or both eyes, involving the middle, front, back, or entire eye. - You had active eye inflammation at some point in the last 180 days, shown by specific levels of inflamm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02374060 · JHSPH Center for Clinical Trials Phase 3 · 4 countries Completed
Completed Phase 3 Est. completion 30 August 2017
🇦🇺 AU🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have uveitis (inflammation inside the eye) that is not caused by an infection — it can be currently active or not active - You have swelling in the central part of the retina (the back of the eye), as measured by a special eye scan called OCT - Your vision in the affecte...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02623426 · JHSPH Center for Clinical Trials Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 27 October 2021
🇦🇺 AU🇨🇦 CA🇮🇳 IN🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have non-infectious uveitis (inflammation inside the eye) that is inactive or only very mildly active, and has been that way for at least 4 weeks - You have swelling in the central part of your retina (called macular edema), confirmed b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03816397 · Nisha Acharya Phase 4 · 3 countries Completed
Completed Phase 4 Est. completion 23 January 2025
🇦🇺 AU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are willing to follow all study rules and are available for the full length of the study - You are 2 years of age or older - You were diagnosed with juvenile idiopathic arthritis (a type of childhood arthritis) or chronic eye inflammation before age 16 (you can be older t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT06723106 · Chugai Pharmaceutical Phase 1 · 19 countries By Invitation
By Invitation Phase 1 Est. completion 28 February 2028
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇭🇷 HR🇨🇿 CZ🇫🇷 FR🇩🇪 DE +11 more

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the study - You must have already completed 4 doses of a treatment called RAY121 in a previous related trial (RAY902CT) and shown a positive response to it - You must be able to follow the study's rules...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05200715 · University of Siena Not Applicable · 22 countries Recruiting
Recruiting Not Applicable Est. completion 6 August 2026
Algeria🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇳 CN🇨🇴 CO🇪🇬 EG🇩🇪 DE +14 more

**Who might be able to join this trial:** - You have been diagnosed with a rare inherited inflammatory disease, confirmed by both your symptoms and a genetic test - You have been diagnosed with one of the following specific inflammatory conditions: Familial Mediterranean Fever, Behçet's disease, Still's disease, PFAPA...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06371417 · Chugai Pharmaceutical Phase 1 · 20 countries Recruiting
Recruiting Phase 1 Est. completion 31 March 2027
🇦🇺 AU🇦🇹 AT🇧🇬 BG🇨🇦 CA🇭🇷 HR🇨🇿 CZ🇫🇷 FR🇩🇪 DE +12 more

**Who might be able to join this trial:** - People aged 18 to 75 who are willing and able to sign a consent form and follow the study requirements (people joining the Bullous Pemphigoid group may be up to age 85, provided they meet a minimum level of physical functioning) - Women who could become pregnant must agree t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06395285 · Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇦🇺 AU🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - You understand what the study involves and what will be required of you to participate. - Your body mass index (BMI) is between 18.0 and 35.0 (a measure of weight relative to height). - You have had genetic testing that confirmed you carry a gene change (mutation) linked to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03207815 · Gilead Sciences Phase 2 · 7 countries Terminated
Terminated Phase 2 Est. completion 29 December 2020
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇮🇱 IL🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of eye inflammation (uveitis) that is not caused by an infection, affecting the middle, back, or entire part of the eye - Your eye inflammation is still active at your first visit, meaning it has not fully responded after at least...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04088409 · Eli Lilly and Company Phase 3 · 5 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 17 July 2023
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with a type of eye inflammation linked to juvenile idiopathic arthritis (JIA-U) or a long-term eye condition called chronic anterior uveitis that tested positive for a certain antibody (ANA), without other body-wide symptoms. - You currently have acti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00130637 · National Eye Institute (NEI) Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 May 2008
🇺🇸 US

**Who might be able to join this trial:** - You are between 6 and 18 years old (inclusive) - You have been diagnosed with eye inflammation (uveitis) that is linked to a condition called juvenile idiopathic arthritis (JIA), and it requires anti-inflammatory treatment given 3 or more times a day - Your uveitis is still...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00280826 · National Eye Institute (NEI) Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 1 February 2009
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a serious eye inflammation condition (uveitis, affecting the middle or back of the eye) for at least three months, which is causing ongoing fluid build-up in the central part of your retina (macular edema) in one or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00476593 · Norwegian University of Science and Technology Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 1 December 2009
🇳🇴 NO

**Who might be able to join this trial:** - Healthy adults who would like to take part as volunteers - Adult patients who have been diagnosed with anterior uveitis (inflammation at the front of the eye) and wish to participate **Who may not be able to join:** - Patients with anterior uveitis who also have other health...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00483184 · Nobel Pharmaceuticals Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 April 2008
Turkey (Türkiye)

**Who might be able to join this trial:** - You are male, or a female who is not pregnant and not breastfeeding. - You have been diagnosed with Behçet's Disease and meet the recognised international diagnostic criteria for this condition. - You have had mouth ulcers related to Behçet's Disease for at least 12 months. -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00498355 · University of California, San Francisco Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 January 2009
🇺🇸 US

**Who might be able to join this trial:** - You are able to give written consent and are willing to take part in all study visits and assessments for the full length of the study - You are 18 years of age or older - You have a history of uveitis (eye inflammation) that is not caused by infection, and you have had fluid...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00525902 · Oregon Health and Science University Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 September 2010
🇺🇸 US

Who might be able to join this trial: - You have an autoimmune eye condition called uveitis that is serious enough to threaten your vision. - Your uveitis has not responded to prednisone (a steroid) and at least one other medication that suppresses the immune system (such as methotrexate, azathioprine, mycophenolate mo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00685399 · Novartis Pharmaceuticals Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 1 September 2013
🇩🇪 DE🇺🇸 US

Who might be able to join this trial: - You have active uveitis (an inflammatory eye condition that is currently flaring up, not in remission). - Your uveitis affects the middle, back, or the whole of the eye, and is severe enough that your doctor has determined you need medication that affects your whole immune system...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00826618 · University of Miami Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 1 September 2012
🇺🇸 US

Who might be able to join this trial: - You must be able to give written consent and participate in all study visits for the full length of the study - You must be over 18 years old - The eye being studied must have uveitis (eye inflammation) that is not caused by an infection - Your uveitis treatment must have been st...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00866359 · Amgen Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 1 May 2012
Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Behçet Disease, confirmed using internationally recognised diagnostic criteria - You have had 2 or more mouth ulcers in the 28 days before your screening appointment (whether or not you are currently being treated) - You have 2 or more mouth ulce...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00995709 · Novartis Pharmaceuticals Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 July 2010
🇪🇬 EG🇫🇷 FR🇩🇪 DE🇬🇷 GR Hong Kong🇮🇳 IN🇮🇱 IL🇮🇹 IT +9 more

**Who might be able to join this trial:** - You have been diagnosed with Behçet's disease and have had repeated episodes of eye inflammation (uveitis) in at least one eye. - You have had more than 2 flare-ups of moderate-to-severe eye inflammation (affecting the middle or back of the eye, or the whole eye) in the past...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01138657 · AbbVie (prior sponsor, Abbott) Phase 3 Completed
Completed Phase 3 Est. completion 1 July 2014

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with a non-infectious type of eye inflammation (uveitis) affecting the middle, back, or entire area of the eye. - Your eye inflammation is still active despite taking oral steroid pills (prednisone or equivalent, be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01148225 · AbbVie Phase 3 Completed
Completed Phase 3 Est. completion 21 May 2018

**Who might be able to join this trial:** - You must have previously enrolled in one of two specific related studies (called M10-877 or M10-880), and either reached what those studies called a "Treatment Failure" point, or fully completed one of those studies. **Who may not be able to join:** - You left the previous r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01154010 · Massachusetts Eye and Ear Infirmary Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 1 April 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed by a doctor with anterior uveitis (also called iritis), which is inflammation at the front of the eye - Your uveitis is not caused by an infection - You are generally in good health apart from this eye condition - You are 18 years of age or older - An...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01201798 · Alcon Research Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 1 August 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of eye inflammation (called anterior uveitis) that originates from within the body, affecting at least one eye. - There is a significant level of inflammation visible in the front part of at least one eye, measured by the number of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01232920 · University of California, San Francisco Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 1 June 2012
🇮🇳 IN

**Who might be able to join this trial:** - You have uveitis (eye inflammation) that is not caused by an infection, affecting the front, middle, back, or entire part of the eye. - Your uveitis has been active within the last 60 days, meaning signs of inflammation were detected during an eye exam. - You are currently ta...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01279954 · Oregon Health and Science University Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 June 2017
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a serious eye condition caused by the immune system attacking the eye (called autoimmune uveitis) that is threatening your vision - You have already tried prednisone (a steroid medication) and at least one other medication that suppresses the immune s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01358266 · Santen Inc. Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 1 September 2016
🇦🇷 AR🇦🇹 AT🇧🇷 BR🇨🇱 CL🇨🇴 CO🇫🇷 FR🇩🇪 DE🇮🇳 IN +9 more

**Who might be able to join this trial:** - You have been diagnosed with active uveitis (inflammation inside the eye) that has been confirmed by a doctor - You are 18 years of age or older - You are willing and able to sign a consent form agreeing to take part in the study - Your vision meets a specific level when test...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01376362 · National Eye Institute (NEI) Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 February 2012
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be willing and able to read, understand, and sign a consent form for the study. - You must have been diagnosed with swelling in the central part of the retina (a condition called CME) caused by eye inflammation (uveitis) in at leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01475643 · Bausch & Lomb Incorporated Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 2 June 2017
🇺🇸 US

Who might be able to join this trial: - Children who are scheduled for a straightforward, routine cataract surgery (surgery to remove a cloudy lens in the eye) Who may not be able to join: - Children who have a serious eye condition, or any other unstable health condition that the doctor believes could interfere with...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01526889 · Novartis Pharmaceuticals Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 16 February 2017
🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older (male or female) - You have active inflammation inside at least one eye (called non-infectious uveitis) that needs stronger treatment to control it - You have a specific type of clouding in the jelly-like part of your eye (called vitreous haze), o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01532570 · Tanabe Pharma Corporation Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 1 May 2014
🇯🇵 JP

Who might be able to join this trial: - You have been diagnosed with Behcet's disease (either the full or partial form) based on Japanese Ministry of Health guidelines. - You have serious complications of Behcet's disease (called "special lesions") that have not responded to standard treatments, or you are unable to to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01694186 · EyePoint Pharmaceuticals, Inc. Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 26 March 2018
🇩🇪 DE🇭🇺 HU🇮🇳 IN🇮🇱 IL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are male or non-pregnant female, aged 18 or older at the time of signing consent - People who have a history of recurring non-infectious uveitis (inflammation inside the eye) affecting the back of the eye, lasting more than 1 year, in one or both eyes - People who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01789320 · Clearside Biomedical, Inc. Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 March 2015
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a non-infectious form of uveitis (inflammation inside the eye) affecting the middle, back, or entire part of the eye **Who may not be able to join:** - You have had an injury to the eye being studied in the last 6 months - You have received a ste...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01900431 · Sanofi Phase 2 · 6 countries Completed
Completed Phase 2 Est. completion 1 July 2015
🇨🇿 CZ🇫🇷 FR🇮🇹 IT🇪🇸 ES Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You have a non-infectious type of eye inflammation (uveitis) affecting the middle, back, or entire part of the eye. - Your eye condition was active at the time of screening, or showed signs of activity within the 3 months before your sc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02049476 · Johns Hopkins University Phase 4 · 1 country Completed
Completed Phase 4 Est. completion 30 June 2018
🇺🇸 US

**Who might be able to join this trial:** - You have active uveitis (inflammation inside the eye) affecting the middle or back of the eye that is serious enough to threaten your vision, and your doctor is planning to treat it with strong steroid medicines along with other immune-suppressing drugs. - You are already tak...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02251938 · Santen Inc. Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 1 November 2017
🇦🇹 AT🇫🇷 FR🇮🇳 IN🇮🇹 IT Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You previously took part in the SAKURA study - You saw a benefit from the treatment you received during the SAKURA study - You are able to give your written consent to participate and can attend all required study visits **Who may not be able to join:** - Your eye inflammati...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02255032 · Clearside Biomedical, Inc. Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 December 2015
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with uveitis (inflammation inside the eye) that is not caused by an infection. - You have been diagnosed with swelling in the central part of your retina (called macular edema) that is related to your non-infectious uveitis. Who may not be able to join: -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02406209 · Aldeyra Therapeutics, Inc. Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 April 2016
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with non-infectious anterior uveitis (inflammation at the front of the eye that is not caused by an infection) - The level of inflammation in the front part of your eye falls within a certain range (graded 1 to 3 by your eye doctor) - The pressure in y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02482129 · Alcon Research Phase 2 Completed
Completed Phase 2 Est. completion 21 March 2016

Who might be able to join this trial: - You must be willing and able to sign a consent form agreeing to take part in the study. - You must have been diagnosed with non-infectious acute anterior uveitis (inflammation at the front of the eye not caused by infection) in at least one eye. - The level of inflammation in the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02595398 · Clearside Biomedical, Inc. Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 18 January 2018
🇮🇳 IN🇮🇱 IL🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of eye inflammation called non-infectious uveitis (this includes inflammation affecting the front, middle, back, or all layers of the eye) - You have swelling in the central part of your retina (the back of the eye) that is linked to your u...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02746991 · EyePoint Pharmaceuticals, Inc. Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 4 October 2019
🇮🇳 IN

Who might be able to join this trial: - People who are male or non-pregnant female, aged 18 or older at the time of signing the consent form - People who have had recurring non-infectious inflammation inside one or both eyes (affecting the back of the eye, with or without front-of-eye involvement) for more than 1 year...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02748512 · EyePoint Pharmaceuticals, Inc. Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 17 August 2017
🇺🇸 US

Who might be able to join this trial: - You are male or a non-pregnant female aged 18 or older at the time of signing the consent form - At least one of your eyes has a history of non-infectious uveitis (inflammation inside the eye not caused by infection) that affected the back part of the eye - You are able to unders...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02756650 · Novartis Pharmaceuticals Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 31 January 2019
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 60 years old and have been diagnosed with Behçet's Disease using recognised international diagnostic criteria - You have recently had a worsening (flare-up) of Behçet's Disease affecting either large blood vessels or the brain/nervous system - **For ne...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02764697 · Tampa Bay Uveitis Center, LLC Phase 4 · 1 country Completed
Completed Phase 4 Est. completion 7 December 2016
🇺🇸 US

Who might be able to join this trial: - You must be able to understand and sign a consent form agreeing to take part in the study - You must be 18 years old or older - Both men and women can take part - You must have had a negative tuberculosis (TB) test (either a skin test or a blood test) within the past 3 months - Y...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02911116 · National Eye Institute (NEI) Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 5 March 2020
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You are able to understand and sign a consent form agreeing to take part in the study. - You have had a recent tuberculosis (TB) skin or blood test that came back negative (done within the last 3 months), or you had a latent (inactive) TB...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02952001 · Clearside Biomedical, Inc. Not Applicable · 2 countries Completed
Completed Not Applicable Est. completion 22 May 2018
🇮🇳 IN🇺🇸 US

Who might be able to join this trial: - You must already be taking part in a related study called CLS1001-301 and have completed it up to Visit 8 (the 6-month point) - You must be willing and able to sign a consent form and agree to follow the study instructions and attend all required appointments Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03020992 · UCB Biopharma SRL Phase 4 · 5 countries Completed
Completed Phase 4 Est. completion 4 December 2019
🇨🇿 CZ🇩🇪 DE🇳🇱 NL🇵🇱 PL🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with axial Spondyloarthritis (a type of inflammatory spinal arthritis) as an adult, with symptoms lasting at least 3 months, and your diagnosis meets specific international criteria - Your disease is currently active, shown by a symptom score of 4 or...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03097315 · Clearside Biomedical, Inc. Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 24 January 2018
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with uveitis (inflammation inside the eye) — either currently active or not currently active — that is not caused by an infection. This includes uveitis affecting different parts of the eye (front, middle, back, or the whole eye). - You are able to rea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03133767 · Nicholas M Mohr Phase 4 · 1 country Completed
Completed Phase 4 Est. completion 1 November 2017
🇺🇸 US

Who might be able to join this trial: - You are being seen in an emergency department (ER) - Your main reason for visiting the ER is nausea, vomiting, diarrhea, stomach pain, dehydration, heat stroke, or heat exhaustion - The ER doctor has agreed that you can receive two liters of fluid (through a drip/IV) - The ER doc...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03584724 · Eye Pharma Early Phase 1 · 1 country Completed
Completed Early Phase 1 Est. completion 20 August 2020
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a type of eye inflammation (uveitis) linked to a specific genetic marker called HLA-B27 - Your eye inflammation is currently not in an active flare-up (non-acute phase) - You have had at least one previous episode of this eye inflammation returning W...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT03634475 · Panoptes Pharma GmbH Phase 2 · 5 countries Completed
Completed Phase 2 Est. completion 1 November 2018
🇦🇹 AT🇧🇪 BE🇩🇪 DE🇳🇱 NL🇬🇧 GB

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a long-term eye condition affecting the back, middle, or entire interior of the eye (called chronic posterior uveitis, intermediate uveitis, or panuveitis) - You can be either male or female Who may not be able to join...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03811366 · University of Sao Paulo Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 31 January 2017
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed by a doctor with Vogt-Koyanagi-Harada disease (a condition that affects the eyes and other parts of the body) - Your condition started recently and you have not received any treatment for it yet **Who may not be able to join:** - Your Vogt-Koyanagi-Ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03841357 · Duke University Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 22 January 2025
🇺🇸 US

**Who might be able to join this trial:** - You are between 2 and 16.5 years old - A pediatric rheumatologist (a children's joint specialist) has diagnosed you with Juvenile Idiopathic Arthritis (JIA) within the past 6 months - The arthritis has affected 4 or fewer joints from when symptoms started up until joining th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04200833 · Medical University of Graz Not Applicable Completed
Completed Not Applicable Est. completion 1 July 2021

Who might be able to join this trial: - You have been diagnosed with uveitis (eye inflammation) that is linked to a condition called Juvenile Idiopathic Arthritis (JIA) - You have already tried a medication called adalimumab, but it did not work well enough for you Who may not be able to join: - Your eye inflammation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04222712 · Tarsier Pharma Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 24 August 2020
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to give your consent to participate, follow instructions, and attend all required appointments for the full length of the study - You have been diagnosed with active non-infectious anterior uveitis (inflammation at the front of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04976777 · AbbVie Phase 3 · 1 country Completed
Completed Phase 3 Est. completion 9 February 2022
🇺🇸 US

Who might be able to join this trial: - You have swelling in the central part of your eye (called macular edema) caused by a blocked vein in your retina (either a branch or central retinal vein occlusion) or by diabetes. Who may not be able to join: - You have a condition in the eye being studied that means you cannot...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05042609 · Tarsier Pharma Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 29 June 2023
🇫🇷 FR🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - You are male or female and up to 75 years old (if the trial site is in the US), or between 18 and 70 years old (if the trial site is in Europe). - You have been diagnosed with a specific type of active eye inflammation (non-infectious anterior uveitis) with a moderate level o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05286203 · University of California, San Francisco Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 31 January 2024
🇺🇸 US

Who might be able to join this trial: - You have an eye infection that is causing inflammation inside the eye (such as uveitis affecting the front, middle, or back of the eye, or the whole eye) - You have a suspected infection inside the eye that developed after eye surgery (known as post-operative endophthalmitis) - T...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05105347 · Peking Union Medical College Hospital Phase 4 Not Yet Recruiting
Not Yet Recruiting Phase 4 Est. completion 31 December 2026

**Who might be able to join this trial:** - You have been diagnosed with Behçet's disease (a rare inflammatory condition) that meets specific international diagnostic criteria from 2013, and you have recently had a flare-up of severe eye inflammation affecting the back or all layers of the eye. - You are currently taki...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05651880 · University Hospital, Rouen Phase 3 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 1 December 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a specific type of eye inflammation (uveitis) that is not located at the front of the eye and is not caused by an infection. - Your uveitis has not improved despite trying at least one biological medication (such as anti-TNF alpha or tocilizumab)....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05874505 · Assistance Publique - Hôpitaux de Paris Phase 2 Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 1 November 2026

**Who might be able to join this trial:** - You are 18 years old or older - You are willing and able to sign a consent form before any study procedures begin - You have been diagnosed with Behçet's disease (based on recognised international criteria) or have a history of mouth/genital ulcers (aphthosis) - You have bee...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05960864 · Southwest Hospital, China Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 August 2025

**Who might be able to join this trial:** - You have been diagnosed with Crohn's disease - You have been diagnosed with acute anterior uveitis (a type of eye inflammation) - You have been diagnosed with psoriatic arthritis that also affects the spine or back (axial involvement) - You have been diagnosed with reactive a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05984758 · Institute of Child Health Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 July 2026
🇬🇧 GB

Who might be able to join this trial: - You have been recently diagnosed with Juvenile Idiopathic Arthritis (JIA) within the last 12 months, and your doctors have recommended regular eye check-ups to watch for signs of eye inflammation - The child is between 2 and 12 years old Who may not be able to join: - The child...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06258915 · Assistance Publique - Hôpitaux de Paris Phase 3 Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 1 June 2027

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with non-infectious uveitis (inflammation in the middle, back, or throughout the eye) in at least one eye, confirmed by your medical history - Your uveitis has shown signs of being active in the past 3 months, even w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06390436 · Centre Hospitalier Universitaire de Saint Etienne Phase 4 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 4 Est. completion 1 December 2029
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have given your informed agreement and signed the study consent form - You have been diagnosed with a specific type of eye inflammation called non-infectious uveitis, identified using a standard set of medical criteria - Your eye condition...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06743906 · Assiut University Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 March 2026

**Who might be able to join this trial:** - You must be over 18 years old. - You must be able to give your own informed consent to take part. - You must have been diagnosed with posterior uveitis (inflammation at the back of the eye, which may be caused by an infection or have no known infectious cause). **Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06836817 · Minia University Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 15 May 2025

Who might be able to join this trial: - Group I: You may be eligible if you meet the international criteria for Behcet's Disease, as defined by the International Study Group in 1990 (confirm with trial site) - Group II: You may be eligible if you do not have a diagnosis of Behcet's Disease Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06920017 · Assiut University Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 April 2026

Who might be able to join this trial: - You are under 18 years old and have been diagnosed with uveitis (inflammation inside the eye) - You are able to take part in the study activities Who may not be able to join: - You are 18 years old or older - You have had a serious penetrating injury to the eye in the past - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06925698 · Marmara University Phase 3 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 1 April 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 50 years old. - You have been diagnosed with Behçet's Disease using the standard international diagnostic criteria (ISG criteria). - You have not previously had blood vessel complications from Behçet's Disease, or you have not been treated with immune-s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07018206 · CARE ARTHRITIS LTD. Phase 4 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 4 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older at the time of their screening visit. - People who are willing and able to understand the study requirements and sign a consent form before any study procedures begin. - People who have been diagnosed with axial spondyloarthritis (a type of inflammatory sp...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07136805 · VivaVision Biotech, Inc Phase 3 Not Yet Recruiting
Not Yet Recruiting Phase 3 Est. completion 31 December 2026

**Who might be able to join this trial:** - You are between 18 and 70 years old (inclusive) at the time of signing the consent form - At your screening visit, one of your eyes has been diagnosed with non-infectious anterior uveitis (either an acute episode or a recurring acute episode, affecting one eye only) - At your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07157189 · Assiut University Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 30 November 2027

**Who might be able to join this trial:** - You have been diagnosed with Behçet's Disease (BD) and meet specific international diagnostic guidelines, which means you have recurring mouth sores *plus* at least two of the following: recurring genital sores, eye problems (such as inflammation inside the eye or problems wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07298174 · IRCCS San Raffaele Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 January 2028

Who might be able to join this trial: - You must be over 18 years old - Both men and women are welcome to join - You must have a confirmed diagnosis of one of the following eye conditions: age-related macular degeneration, diabetic retinopathy, myopia (short-sightedness), pachychoroid spectrum disease (a group of condi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07423442 · Nantes University Hospital Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a non-infectious type of eye inflammation (uveitis) that affects the back part of the eye - You have swelling in the central part of your eye (macular edema) or ongoing inflammation at the back of your eye related to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07427628 · Quan Dong Nguyen Phase 1 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 1 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 70 years old at the time of giving consent - People who weigh at least 40 kg at the time of giving consent - People who are able to understand and sign a consent form, and who are willing and able to attend all required visits and procedures - People diagno...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07513623 · University of California, San Francisco Phase 2 · 3 countries Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 31 December 2031
🇹🇼 TW🇹🇭 TH🇺🇸 US

Who might be able to join this trial: **For the first part of the trial (Trial I):** - Adults of legal adult age (18 or older in the United States; 20 or older in Thailand and Taiwan) at the time of joining - People who currently have active inflammation at the front of the eye (anterior uveitis), with a level of eye...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01277419 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine) or juvenile spondyloarthritis (the same condition diagnosed in young people). - You have been diagnosed with Crohn's disease (a long-term condition causing inflammation in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01746537 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You have a condition called uveitis (inflammation inside the eye) and are being seen at the Cole Eye Institute. **Who may not be able to join:** - You are unable to give your informed consent to take part, including if English is not your spoken language or if you have a cog...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02357238 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with uveitis (inflammation inside the eye). - You have been diagnosed with a type of uveitis caused by an infection, such as toxoplasmosis (a parasitic infection affecting the eye) or herpes-related retinal disease. Who may not be able to join: - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02593565 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a woman aged 18 or older who has been diagnosed with one of the following conditions: Behçet's disease, Central nervous system (CNS) vasculitis, Cryoglobulinemic vasculitis, Eosinophilic granulomatosis with polyangiitis (also known as Churg-Strauss Syndrome), Giant Ce...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02706704 · American University of Beirut Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇱🇧 LB

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with a non-infectious form of uveitis (inflammation in the middle, back, or throughout the eye — not the front only). - Your eye inflammation is still active despite taking steroid tablets (such as prednisone at 10...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03399175 · University of Sao Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 May 2023
🇧🇷 BR

"Who might be able to join this trial: - You have been diagnosed with acute Vogt-Koyanagi-Harada disease (a condition where the immune system attacks the eyes, ears, and skin, causing sudden inflammation) Who may not be able to join: - You are unable or unwilling to cooperate with the study requirements (confirm with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04334031 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 July 2031
🇫🇷 FR

**Who might be able to join this trial:** - You are being treated for an immune-mediated inflammatory disease (a condition where the immune system causes inflammation) at one of the participating departments at Lille University Hospital (dermatology, internal medicine, neurology, lung care, or rheumatology) - You are c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04402086 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: **For people with rheumatic conditions:** - You are 18 years old or older and have been diagnosed with a rheumatic autoimmune disease, such as rheumatoid arthritis, lupus, psoriatic arthritis, Sjogren's syndrome, scleroderma, or a similar condition (a fuller list can be confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04528082 · Amgen Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 7 February 2030
🇫🇷 FR🇬🇷 GR🇮🇱 IL🇮🇹 IT🇪🇸 ES🇨🇭 CH Turkey (Türkiye)🇬🇧 GB

**Who might be able to join this trial:** - The participant must be a child or teenager between 2 and 17 years old at the time of joining the trial - The participant must have been diagnosed with Behçet's disease (a condition that causes recurring sores and inflammation in the body) using standard international diagnos...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05153057 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇫🇷 FR

**Who might be able to join this trial:** - The condition affects both eyes. - There are at least three specific spots (called "birdshot lesions") below or to the inner side of the optic nerve in at least one eye. - There is only a small amount of inflammation in the front part of the eye (a low level, confirmed by an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05388838 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have given your free, written consent to participate before any study-related tests are done - You are covered by a social security or health insurance system - You have a condition affecting one or both eyes that falls...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05474729 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with an autoimmune disease that has affected your vision (such as reduced vision or damage to the back of the eye). - You are between 18 and 60 years old. - You are willing and able to sign a consent form and attend all required follow-up visits. **Wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05486468 · Texas Retina Associates Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a man or a woman who is not pregnant, are at least 18 years old, are in good general health, and are able to read and understand the consent forms. - You are willing and able to attend all scheduled appointments and follow the study plan. - You have been diagnosed wit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05590416 · Tianjin Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have never had tuberculosis (TB) in the past, and do not currently have an active or dormant TB infection - You have been diagnosed with Vogt-Koyanagi-Harada (VKH) disease for less than one month - You have been treated with steroid t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05592717 · Tianjin Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are a man or woman aged 18 to 70 years old and are generally in good health - You have inflammation inside one or both eyes (a condition called uveitis) that affects the back part of the eye and is not caused by an infection - You have signs of active eye inflammation bef...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05767047 · Amgen Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 17 March 2036
🇬🇷 GR🇮🇱 IL🇪🇸 ES Turkey (Türkiye)

**Who might be able to join this trial:** - You (or your child) agreed to take part and gave signed consent or assent to join the study - You must have completed 52 weeks of treatment in the main (core) study and be under 18 years old at the time of signing the consent form - Your BMI (a measure of body weight relative...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05845723 · Peking Union Medical College Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to read and sign a consent form before any study activities begin - You are between 18 and 65 years old (male or female) - You have been diagnosed with Behçet's Disease according to the 2013 international classification criteria - You have been confirmed by ul...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05904301 · Santé Arménie French-Armenian Research Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
Armenia

**Who might be able to join this trial:** - You have been officially diagnosed with at least one of the following conditions: Behçet's disease, ANCA-positive vasculitis, Takayasu arteritis, Giant cell arteritis, Systemic sclerosis, Sjögren's syndrome, Rheumatoid arthritis, Spondylarthritis (including psoriatic, ankylos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06145893 · Ganzhou Hemay Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 May 2026
🇨🇳 CN

Who might be able to join this trial: - People who have read and voluntarily signed the consent form for this study - People aged 18 to 75 years old (inclusive), of any gender - People who have been diagnosed with Behçet's disease using the ICBD-2013 diagnostic criteria - People who have at least 2 mouth ulcers at thei...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06161415 · Quan Dong Nguyen Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are willing and able to give your consent and follow the study's instructions - You are already scheduled to have a specific type of eye surgery called a vitrectomy (an operation inside the eye) - The pressure inside your eye being studied...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06273748 · Meyer Children's Hospital IRCCS Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 February 2032
🇧🇪 BE🇬🇷 GR🇮🇹 IT Turkey (Türkiye)🇺🇸 US

Who might be able to join this trial: - You were diagnosed with long-term (chronic) eye inflammation (uveitis) that is not caused by an infection, and this diagnosis was made before you turned 16 - You (or your parent/guardian if applicable) have signed a consent form agreeing to take part in the trial Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06285539 · UMC Utrecht Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older (but under 65) - You have been diagnosed with one of the following rare inflammatory conditions, with active disease: - **Behçet's disease** that does not currently involve life-, organ-, or sight-threatening symptoms, but is considered activ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06539481 · Alimera Sciences Phase 4 · 3 countries Recruiting
Recruiting Phase 4 Est. completion 15 July 2026
🇩🇪 DE🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You are between 6 and 17 years old (at the time of giving consent to join) - You have a non-infectious form of uveitis (inflammation inside the eye that is not caused by infection) affecting the middle or back of the eye, and it has come back at least once a year - Your uveit...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06587828 · TScan Therapeutics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with, or are suspected to have, one of the following conditions: Crohn's disease, ulcerative colitis, celiac disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, multiple sclerosis, scleroderma, systemic sclerosis with lung involvemen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06720376 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2028
Turkey (Türkiye)

Who might be able to join this trial: - You have been diagnosed with uveitis (inflammation inside the eye) Who may not be able to join: - You were diagnosed with spondyloarthritis (a type of inflammatory joint disease) before your uveitis episode occurred - Your uveitis is caused by an infection Important: Always ver...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06721234 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with Behcet's Disease according to official international guidelines - You are 18 years of age or older - You are able to communicate and answer questions during the study - You are willing and able to give your formal written agreement to take part Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06780462 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 24 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with Behçet's Syndrome (BS) based on recognised international diagnostic standards - You have been diagnosed with a deep vein blood clot (either for the first time or as a return of a previous clot), confirmed by an imag...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06794008 · Peking University People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old (inclusive) who weigh at least 45 kg, of any gender. - People who have been diagnosed with one of the following conditions using recognised medical classification systems: Systemic lupus erythematosus (SLE), Sjögren's syndrome, Inflammatory myo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06849908 · Peking Union Medical College Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with intestinal Behçet's syndrome (a condition causing inflammation and ulcers in the gut) based on recognized international diagnostic criteria, confirmed by a camera examination of your bowel. - Your symptoms are currently active and scored at a cer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06974162 · Moorfields Eye Hospital NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 November 2026
🇬🇧 GB

Who might be able to join this trial: - You must be 18 years of age or older and able to give your own consent to participate - Your doctors have not yet been able to reach a clear diagnosis through standard medical care - You currently have active inflammation in your eye(s) that puts your vision at risk - Your doctor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07065747 · Oregon Health and Science University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - You have active eye inflammation and have been diagnosed with one of several specific eye conditions linked to conditions such as spondyloarthritis, juvenile idiopathic arthritis, herpes simplex virus, or other types of uveitis (an inflammation inside the eye). - You have floater...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07077304 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You are able to understand and agree (or not object) to taking part in the study - You have been referred for a cardiac MRI and/or nuclear heart imaging scan - You are being investigated for a suspected heart condition related to inflammation or im...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07145008 · University of Baghdad Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 June 2025
Iraq

Who might be able to join this trial: - You have a non-infectious eye inflammation condition (uveitis) that has caused swelling in the central part of your eye (the macula) - The swelling in your eye has been present for less than four months - The swelling in your eye has continued even after the eye inflammation itse...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07276087 · ÖZLEM NUR TOK YAMAN Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
Turkey (Türkiye)

Who might be able to join this trial: - You are 18 years of age or older. - You have been diagnosed with Takayasu arteritis (a disease affecting the large blood vessels) based on recognised medical criteria, OR you have been diagnosed with Behçet's disease (a condition causing inflammation in blood vessels and other pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07285070 · Novaliq GmbH Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are willing and able to sign a consent form agreeing to take part in the trial - You have been diagnosed with active non-infectious anterior uveitis (inflammation at the front of the eye that is not caused by infection) that requires sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07375940 · Meyer Children's Hospital IRCCS Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2036
🇮🇹 IT🇬🇧 GB

Who might be able to join this trial: **For people with Behçet's Disease (BD):** - You have been diagnosed with Behçet's Disease based on at least one recognised set of medical classification criteria - You are between 6 months and 70 years old - You (or your legal guardian, if you are a child) have signed a written c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07518134 · Jaeb Center for Health Research Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Children under 17 years old who have been recently diagnosed with uveitis (an eye inflammation condition) within the last 6 months - Children and young people under 18 years old who were diagnosed with uveitis more than 6 months ago - People with any type of uveitis, whether...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07547995 · Changchun GeneScience Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 December 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older, of any gender - People who have been diagnosed with non-infectious uveitis affecting the middle, back, or whole eye (not just the front), with a diagnosis history of more than one year - People who have active disease at the start of the trial while takin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07552012 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand the trial procedures, are willing to take part, can communicate with the research team, and are able to follow all study requirements, including signing a consent form. - You are between 18 and 70 years old (inclusive) at the screening visit. - At...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07662603 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 September 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are a teenager (adolescent patient) - You have been diagnosed with Behçet's disease (a condition that causes inflammation in blood vessels and other parts of the body) - You have already had a surgery called pulmonary endarterectomy (an operation to remove blockages from...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07663331 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older (any gender) - You have been diagnosed with active, non-infectious uveitis (inflammation inside the eye) affecting the middle, back, or entire eye, with signs of active inflammation confirmed by an eye doctor - You have been taking oral stero...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07702123 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 September 2026
🇪🇬 EG

Who might be able to join this trial: - Women who have been diagnosed with metabolic syndrome - Women who have been diagnosed with Behçet's disease (a rare disorder that causes blood vessel inflammation) Who may not be able to join: - Women who have a psychiatric condition or mental health disorder (confirm with trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07702149 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 September 2026
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with Behçet's disease (a rare disorder that causes blood vessel inflammation throughout the body) - People who have been diagnosed with obesity - People who experience tinnitus (ringing or noise in the ears) in both ears, as perceived by the individ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00889421 · Oregon Health and Science University Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 June 2011
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a serious eye condition called autoimmune uveitis that is threatening your vision - Your condition has not responded to standard steroid treatment (prednisone) and at least one other medication that suppresses the immune system, OR you have had to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01032915 · Novartis Pharmaceuticals Phase 3 · 10 countries Terminated
Terminated Phase 3 Est. completion 1 June 2011
🇧🇷 BR🇩🇪 DE🇮🇳 IN🇮🇱 IL🇮🇹 IT🇪🇸 ES🇨🇭 CH Turkey (Türkiye) +2 more

**Who might be able to join this trial:** - You have a calm (non-active) form of chronic, non-infectious eye inflammation affecting the middle, back, or whole eye, with minimal signs of inflammation in both eyes for at least 6 weeks before the screening visit. - You have needed certain medications to control or preven...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01090310 · Novartis Pharmaceuticals Phase 3 · 8 countries Terminated
Terminated Phase 3 Est. completion 1 July 2011
🇧🇷 BR🇩🇪 DE🇮🇳 IN🇮🇱 IL🇪🇸 ES🇨🇭 CH🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must have completed the full 24-week treatment period of the related core study. Who may not be able to join: - You are unwilling or unable to receive repeated injections under the skin. - You are unable or unwilling to follow the study procedures and attend required follow-...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01093846 · Novartis Pharmaceuticals Phase 3 · 14 countries Terminated
Terminated Phase 3 Est. completion 1 January 2011
🇪🇬 EG🇫🇷 FR🇩🇪 DE🇬🇷 GR Hong Kong🇮🇱 IL🇯🇴 JO🇸🇬 SG +6 more

Based on the information provided, the eligibility criteria fields appear to be empty — no inclusion or exclusion criteria were listed in the source text. Here is what I can provide: "Who might be able to join this trial: - No specific inclusion criteria were listed in the provided information (confirm with trial sit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01095250 · Novartis Pharmaceuticals Phase 3 · 13 countries Terminated
Terminated Phase 3 Est. completion 1 October 2010
🇨🇦 CA🇪🇬 EG🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇳 IN🇮🇱 IL🇯🇵 JP +5 more

**Who might be able to join this trial:** - You are 18 years of age or older (male or female) - You have been diagnosed with a long-term, non-infectious eye inflammation condition affecting the middle, back, or entire layer of at least one eye - Your eye inflammation is currently active and at a moderate or higher leve...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01194674 · National Institutes of Health Clinical Center (CC) Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 December 2011
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older. - You must be willing and able to read, understand, and sign a consent form for the study. - You must have been diagnosed with swelling in the central part of your eye (macular edema) caused by eye inflammation (uveitis), requiring treat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01314417 · National Eye Institute (NEI) Phase 2 · 1 country Terminated
Terminated Phase 2 Est. completion 1 January 2013
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be able to understand and sign a consent form agreeing to take part in the study. - You must be willing to follow the study procedures and attend all required visits. - You must have long-lasting swelling in the central part of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02769702 · Washington University School of Medicine Phase 4 · 1 country Terminated
Terminated Phase 4 Est. completion 6 January 2017
🇺🇸 US

**Who might be able to join this trial:** - You have active inflammation at the front of your eye (called anterior uveitis) that is currently being treated with steroid tablets and/or steroid eye drops. **Who may not be able to join:** - Your diabetes is not well controlled. - Your glaucoma (a condition causing increa...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03586284 · University of California, San Francisco Phase 3 · 2 countries Terminated
Terminated Phase 3 Est. completion 13 November 2024
🇹🇭 TH🇺🇸 US

**Who might be able to join this trial:** - Your doctor believes you have a type of eye inflammation called CMV anterior uveitis (swelling at the front of the eye linked to a virus called cytomegalovirus). - A lab test (PCR) has come back positive for CMV in your eye, OR you have had a confirmed CMV eye infection in th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03656692 · Mallinckrodt Phase 4 · 1 country Terminated
Terminated Phase 4 Est. completion 14 July 2020
🇺🇸 US

**Who might be able to join this trial:** - You are male, or female and currently neither pregnant nor breastfeeding - You have been diagnosed with severe non-infectious uveitis affecting the back of the eye (an inflammatory eye condition not caused by infection) - Your eye condition is still active despite taking oral...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03711929 · Santen Inc. Phase 3 · 4 countries Terminated
Terminated Phase 3 Est. completion 14 June 2022
🇦🇷 AR🇮🇳 IN🇮🇹 IT🇺🇸 US

Who might be able to join this trial: - You have active inflammation in the back part of your eye (called uveitis) that is not caused by an infection Who may not be able to join: - You are a woman who is currently pregnant, breastfeeding, or planning to become pregnant - Your eye inflammation is caused by, or suspecte...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03580343 · Washington University School of Medicine Phase 2 · 1 country Status unknown
Status unknown Phase 2 Est. completion 1 December 2019
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with uveitis (inflammation inside the eye) - Your uveitis has responded to steroid treatment in the past - Your condition is currently active and requires you to take at least 10mg of prednisone (or an equivalent steroid medication) every day Who may not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Uveitis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

There isn't an organisation dedicated specifically to uveitis patient support. The Centre for Eye Research Australia and the Lions Eye Institute offer clinical and research information instead.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.